Helicobacter hepaticus Does Not Induce or Potentiate Colitis in Interleukin-10-Deficient Mice by Dieleman, L. A. et al.
INFECTION AND IMMUNITY,
0019-9567/00/$04.0010
Sept. 2000, p. 5107–5113 Vol. 68, No. 9
Copyright © 2000, American Society for Microbiology. All Rights Reserved.
Helicobacter hepaticus Does Not Induce or Potentiate Colitis in
Interleukin-10-Deficient Mice
LEVINUS A. DIELEMAN,1* ANNEMARIE ARENDS,1 SUSAN L. TONKONOGY,2 MARIJE S. GOERRES,1
DAVID W. CRAFT,3 WETONIA GRENTHER,2 RANCE K. SELLON,2 ED BALISH,4 AND R. BALFOUR SARTOR1
Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill,1 and Department of
Microbiology, University of North Carolina Hospitals,3 Chapel Hill, and College of Veterinary Medicine,
North Carolina State University, Raleigh,2 North Carolina, and Departments of Surgery
and Microbiology, University of Wisconsin, Madison, Wisconsin4
Received 15 October 1999/Returned for modification 22 December 1999/Accepted 6 June 2000
Helicobacter hepaticus has been reported to induce colitis, hepatitis, and hepatocellular carcinoma in several
different murine models. The aim of this study was to determine if H. hepaticus will cause colitis in monoas-
sociated mice lacking the interleukin-10 gene (IL-102/2 mice) and potentiate colitis in specific-pathogen-free
(SPF) IL-102/2 mice. Germfree IL-102/2 mice on either a mixed (C57BL/6 3 129/Ola) or inbred (129/SvEv)
genetic background were monoassociated with H. hepaticus ATCC 51448 by oral feeding and rectal enemas. In
a second experiment, germfree IL-102/2 mice were colonized with stool from SPF mice that harbored or did
not harbor endogenous H. hepaticus. After 7 to 9 weeks of colonization, weight loss and mortality were assessed,
the colon was isolated for histology and IL-12 secretion, and mesenteric lymph node cells were assessed for
T-cell activation markers. It was found that IL-102/2 mice monoassociated with H. hepaticus for up to 16 weeks
showed almost no histologic colitis or increased IL-12 production. SPF IL-10-knockout mice had no significant
difference in weight loss, mortality rate, histologic scores, colonic IL-12 secretion, or T-cell activation with or
without H. hepaticus. We conclude that H. hepaticus does not induce or potentiate disease in our IL-102/2 mice
and therefore is not required to induce colitis in genetically susceptible hosts.
The pathogenesis of chronic inflammatory bowel diseases is
still poorly understood. In the last decade experimental models
of chronic intestinal inflammation have clarified the concept
that a combination of genetic, environmental, and immuno-
logic factors are necessary to induce and perpetuate these
chronic, spontaneously relapsing diseases (10, 25).
Results in a number of rodent models have conclusively
documented that luminal bacteria are required for chronic
intestinal inflammation (27). For example, mice that lack the
interleukin-10 gene (IL-102/2 mice) develop a spontaneous,
lethal enterocolitis when housed in a conventional environ-
ment (18). However, when these animals are kept under spe-
cific-pathogen-free (SPF) conditions, they develop nonlethal
inflammation restricted to the colon (18, 30), and in a germfree
(sterile) state, IL-102/2 mice fail to develop colitis or mucosal
immune activation (30). These findings elegantly demonstrate
how commensal intestinal bacteria can induce and perpetuate
colitis in a genetically susceptible host. This concept has been
confirmed in several other genetically engineered colitis mod-
els, such as HLA-B27 transgenic rats (22, 33) IL-22/2 mice (24,
29), mice lacking the T-cell receptor a gene (8), and Tgε26
transgenic mice (34), as well as by the absence of chronic small
intestinal ulceration in Lewis rats exposed to indomethacin
(26).
Although these findings suggest that normal intestinal flora
provide the constant antigenic drive for chronic intestinal in-
flammation in susceptible hosts, the possibility of a persistent
pathogenic microbial infection, or an unconventional pathogen
which is difficult to detect, has not been excluded in either hu-
man inflammatory bowel disease or rodent models (3). Among
those pathogens considered potential candidates to induce
chronic intestinal inflammation are Helicobacter species (2).
Helicobacter hepaticus is a widespread contaminant of murine
colonies (31), including genetically engineered mice with coli-
tis, such as our IL-102/2 mice (30). H. hepaticus causes chronic
active hepatitis, hepatocellular adenoma, and carcinoma, es-
pecially in A/JCr mice (13, 37). A/JCr mice experimentally
infected with H. hepaticus sporadically develop cecal inflam-
mation (typhlitis) (15, 38), as do CD45 RBhi reconstituted
SCID mice (3). Also, mice which lack functional T lympho-
cytes, such as athymic nude mice (36), SCID/NCr mice (20),
and RAG-22/2 mice (35), develop colitis after colonization
with H. hepaticus. Other Helicobacter species are also associ-
ated with colitis in SCID mice, such as Helicobacter bilis, re-
sulting in a proliferative typhlitis and colitis (17, 32). Of con-
siderable interest is that a novel urease-negative intestinal
Helicobacter species was cultivated from cotton-top tamarins
with chronic colitis (28), whereas recently another urease-neg-
ative Helicobacter species was isolated and associated with co-
litis in IL-102/2 mice (14).
The aim of the present studies was to investigate whether
H. hepaticus plays an essential or potentiating pathogenetic
role in the development of colitis in susceptible mice with
functioning T cells. Colitis was quantified by clinical, histologic,
and immunologic parameters in germfree IL-102/2 mice, IL-
102/2 mice monoassociated with H. hepaticus ATCC 51448, or
IL-102/2 mice colonized with SPF luminal bacteria with or
without endogenous H. hepaticus recovered from IL-102/2
mice (30). All bacterial colonizations were performed by the
physiologic route of several oral feedings plus rectal swabs.
MATERIALS AND METHODS
Animals. Two sublines of germfree IL-102/2 mice were used in these studies.
One subline is on a mixed (C57BL/6 3 129/Ola) background. The other is on the
129/SvEv inbred background. Both sublines were provided by D. Rennick,
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DNAX, Palo Alto, Calif., and were rederived into germfree conditions by E.
Balish. The genotype was confirmed by analysis of tail tip digests using the PCR
as described previously (30).
Study design. We report here the results of two separate studies designed to
evaluate the role of H. hepaticus in development of colitis in IL-102/2 mice. In
the first study, 2-month-old germfree C57BL/6 3 129/Ola IL-102/2 mice were
transferred to SPF housing conditions. We have previously determined that
colonization of mice at this age with SPF bacteria induced optimal colitis (30).
Transferred mice were maintained for 4 to 5 days in cages that contained sterile
bedding and were fed autoclaved food and water. Afterwards, bedding from
Helicobacter-free SPF mice was added to each cage in order to colonize all mice
with the same SPF flora. Two days later, each mouse received fecal contents from
either endogenous H. hepaticus-positive or H. hepaticus-negative mice. The fecal
pellets were solubilized in sterile phosphate-buffered saline (PBS) and adminis-
tered to each recipient mouse by oral feeding and rectal swabs. This procedure
was repeated three times during a 1-week period. The donors of H. hepaticus-
positive stool were C57BL/6 3 129 Ola IL-102/2 mice housed in SPF conditions
that were found to harbor endogenous H. hepaticus as detected by PCR. This
H. hepaticus strain was the strain originally found in our IL-102/2 mice (30).
Mice were sacrificed 1, 3, or 8 weeks after PCR detection of H. hepaticus DNA
in fecal pellets. Tissue were collected for histology, intestinal fragment culture,
and flow cytometry of mesenteric lymph node cells.
For the second part of the experiment, germfree IL-102/2 mice on the mixed
(C57BL/6 3 129 Ola) background and germfree IL-102/2 inbred 129/SvEv mice
2 months of age were colonized with a well-characterized murine H. hepaticus
strain (ATCC 51448) (15), which was kindly provided by D. Schauer, Massachu-
setts Institute of Technology, Cambridge. The animals were colonized by oral
gavage twice using 1 ml of an H. hepaticus suspension prepared to a McFarland
turbidity standard of 1.0 in PBS. The presence of H. hepaticus in the stool was
documented at the start of as well as during the study and at necropsy by culture
as well as by PCR, as described below. The mice were sacrificed 9 weeks after
successful colonization as documented by PCR and culture of fecal pellets.
Control littermates remained germfree. Also included in the study were IL-102/2
129/SvEv mice which were colonized with H. hepaticus at birth as the offspring of
IL-102/2 mice that were previously monoassociated with H. hepaticus (ATCC
51448) and which were kept in a separate isolator. These animals were killed at
16 weeks of age. Studies were approved by the University of North Carolina at
Chapel Hill Institutional Animal Care and Use Committee.
Cecal bacterial culture. The cecal contents of each mouse were homogenized
in 1 ml of sterile PBS, after which the slurry was passed through a 0.45-mm
syringe tip filter. The filtrate was then cultured for H. hepaticus at 37°C on blood
agar supplemented with trimethoprim, vancomycin, and polymyxin (Remel Labs,
Lenexa, Kans.) under microaerophilic conditions as described previously (13).
PCR of stool and cecal content. Helicobacter DNA was identified in stool or in
cecal contents at necropsy by PCR amplification using primers B38 and B39 as
described by Shames et al. (31). The presence or absence of other Helicobacter
species was determined by PCR using consensus primers C97 and C98, recog-
nizing a broad panel of Helicobacter species as described by Fox et al. (12). To
confirm the presence of bacterial DNA in all specimens, a PCR using primers
PC5 and P3, detecting conserved bacterial 16S ribosomal DNA, was performed
as described previously (39). All primers sequences used are shown in Table 1.
Histopathology. Sections of stomach, duodenum, ileum, various parts of the
colon (representing cecum and proximal and distal colon), and liver were fixed in
10% neutral buffered formalin and stained with hematoxylin and eosin for
histologic scoring. Scoring was conducted in a blinded fashion on a validated
scale of 0 to 4, with 0 representing no inflammation and 4 representing severe
inflammation characterized by widespread infiltration with inflammatory cells,
crypt hyperplasia, distorsion of architecture, and the presence of ulcers and crypt
abscesses as previously described and validated (22, 30). The total colonic his-
tology score was determined by adding the scores for each section of the large
intestine divided by the total number of sections examined.
Colon cultures. Cultures of colon fragments were prepared according to pub-
lished methods (4) as described previously (30). Between 50 and 100 mg of tissue
per well of a 24-well tissue culture plate (Costar) was cultured in duplicate or
triplicate, as tissue permitted, and cultured in 1 ml of complete RPMI medium
as described previously (30). The cultures were incubated at 37°C for 18 h.
Supernatants were collected and stored at 220°C until assayed.
IL-12 assay. Immunoreactive IL-12 p40 in colon culture supernatants was
measured by ELISA, using the commercially available antibodies C15.6 and
biotinylated C17.8 (Pharmingen, San Diego, Calif.) for capture and detection,
respectively of the IL-12 p40 subunit, as previously described (30).
Lymphoid cell preparations and flow cytometry. Mesenteric lymph nodes
(MLN) were isolated and single-cell preparations were prepared by gentle teas-
ing, as previously described (5). Cells were washed and resuspended in complete
medium RPMI 1640 (Tissue Culture Facility, University of North Carolina
Lineberger Cancer Center, Chapel Hill) supplemented with 5% heat-inactivated
fetal calf serum (Irvine Scientific, Santa Ana, Calif.), 2 mM L-glutamine, 1 mM
sodium pyruvate, 0.05 mM 2-mercaptoethanol, and 50 mg of gentamicin (Sigma,
St. Louis, Mo.) per ml. The proportion of CD41 MLN cells that display an
activated and/or memory phenotype was analyzed by two-color flow cytometry
using rat monoclonal anti-mouse CD44, anti-mouse CD45RB, and anti-mouse
CD62L (L-selectin), as described previously (5), as well as anti-CD69 (H1.2F3;
Pharmingen).
Statistics. Statistical analysis was performed using a commercial software
package (InStat; GraphPad Software, San Diego, Calif.). Normally distributed
data are expressed as the mean 6 standard deviation, and differences among
groups were identified by the Student t test; significance was set at a P value of
,0.05. For nonnormally distributed categorical data, comparison of median
values was achieved using a Kruskal-Wallis one-way analysis of variance on
ranks, and group differences were identified by Dunn’s multiple comparison
procedure.
RESULTS
Germfree mice transferred to SPF conditions colonized with
or without H. hepaticus. Germfree IL-102/2 mice were trans-
ferred into SPF housing conditions and then colonized with
intestinal microorganisms from mice that harbor endogenous
H. hepaticus or from mice found to be free of this organism as
determined by PCR. Within 1 week of administering the third
dose of intestinal microorganisms by oral feeding and rectal
swabs, H. hepaticus DNA was detectable in stool samples of the
transferred mice. H. hepaticus DNA remained in fecal pellets
of these mice throughout the study period and was also docu-
mented in cecal contents when the mice were sacrificed 8 to 9
weeks after first confirmation of H. hepaticus DNA in fecal
pellets (Fig. 1). In addition, fecal pellets and cecal contents of
SPF mice colonized with bacteria free of H. hepaticus remained
H. hepaticus negative by PCR. We excluded other known Hel-
icobacter species by performing PCR using primers that recog-
nize consensus sequences of a panel of Helicobacter species
(12).
Within 1 week after colonization with SPF flora without
Helicobacter, C57BL/6 3 129/Ola IL-102/2 mice developed
a significant but moderate mucosal inflammation, especially
prominent in the cecum (median of 2.25 in SPF versus 0 in
germfree IL-102/2 mice; P , 0.001) (Fig. 2A), which progres-
sively increased to submucosal involvement by 3 weeks (medi-









FIG. 1. PCR analysis of H. hepaticus DNA (417 bp) and conserved bacterial
16S ribosomal DNA (721 bp) from cecal contents collected at necropsy from
IL-102/2 mice transferred from germfree to SPF conditions without H. hepaticus
for 8 weeks before sacrifice (IL-102/2, SPF) (n 5 3), from IL-102/2 mice
transferred from germfree to SPF conditions with H. hepaticus for 8 weeks before
sacrifice (IL-102/2, SPF 1 Hh) (n 5 5), or from germfree IL-102/2 mice
monoassociated with H. hepaticus ATCC 51488 for 9 weeks before sacrifice
(IL-102/2, Hh mono) (n 5 4). DNA extracted from a culture of H. hepaticus
ATCC 51488 served as the positive control (pos.), and the PCR mix without
DNA served as the negative control (neg.).
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an score of 3.0) and severe pancolitis with transmural inflam-
mation of the cecum by 8 weeks of bacterial colonization
(median of 4.0) (Fig. 2A and 3). H. hepaticus-infected SPF
IL-102/2 mice had almost identical histologic scores (cecal
medians: 1 week, 2.25; 3 weeks, 2.5; 8 weeks, 4.0); there were
no significantly different inflammatory scores in the H. hepati-
cus-negative group at any time point (Fig. 2A). There was a
similar rapid increase in total colonic inflammation after 1
week of colonization with H. hepaticus-negative SPF flora. To-
tal colonic histology scores from these mice also did not differ
from those for SPF IL-102/2 mice colonized with H. hepaticus
at any time point (Fig. 2B). By 8 weeks after SPF exposure, all
IL-102/2 mice showed similar degrees of weight loss (2.4 6
1.5 g in H. hepaticus-negative mice versus 2.7 6 2.2 g in H.
hepaticus-positive mice). Of note, two of five mice in the
8-week H. hepaticus-negative group died, versus no mortality in
the H. hepaticus-positive group. Liver abnormalities were not
found by histologic assessment in either group. These results
indicate that endogenous H. hepaticus colonization did not
potentiate or accelerate the progressive colitis that develops in
germfree IL-102/2 mice after colonization with SPF bacteria.
Monoassociation with H. hepaticus. Germfree IL-102/2 mice
were successfully monoassociated with H. hepaticus (ATCC
51448) by oral feeding and rectal swabbing, as confirmed by
PCR analysis of the stool during the study and of cecal con-
tents at necropsy (Fig. 1). The persistence of H. hepaticus
colonization was also confirmed by anaerobic culture in all
animals at the end of the study period. The absence of con-
tamination with other organisms was confirmed by Gram stain-
ing and aerobic and anaerobic culture. C57BL/6 3 129/Ola
IL-102/2 mice monoassociated with H. hepaticus for 9 weeks
developed no evidence of colitis (Fig. 2C and 3). Other organs,
including the liver and stomach, also did not show any histo-
logic abnormalities (data not shown). These results were con-
firmed with gnotobiotic IL-102/2 mice on an inbred 129SvEv
genetic background, which did not develop colitis at 9 weeks
after H. hepaticus monoassociation (cecal median score of 0)
and which showed only minimal inflammation of the cecum at
16 weeks of age after monoassociation with H. hepaticus since
birth (cecal median score of 0.25) (Fig. 2C and 3) (this result
was not significantly different from that for germfree controls).
Colonic IL-12 secretion. IL-12 has been shown to play a
pivotal role in the intestinal inflammation that develops in
several different murine models of colitis, including the colitis
that occurs spontaneously in IL-102/2 mice (7, 9, 21). In a
previous study designed to determine if luminal bacteria are
required for development of colitis in IL-102/2 mice, we iden-
tified IL-12 in supernatants of colon fragment cultures from
SPF but not germfree IL-102/2 mice (30). In the present stud-
ies, we asked whether or not H. hepaticus alone or H. hepaticus
as one of the luminal bacterial species influenced the produc-
FIG. 2. Cecal (A) and total colonic (B) inflammatory scores of IL-102/2 mice
on a mixed (C57BL/6 3 129/Ola) background after 1, 3, and 8 weeks of SPF
colonization in the presence or absence of H. hepaticus. Inflammatory scores for
SPF IL-101/1 mice are also shown. Box plots represent median values, 25th and
75th percentiles (boxes), 10th and 90th percentiles (error bars), and outlying
values (circles). (C) Cecal histology scores of IL-102/2 mice on either a mixed
(C57BL/6 3 129/Ola) background or a 129 SvEv background monoassociated
with H. hepaticus for 9 and 16 weeks. Inflammatory scores of germfree IL-102/2
mice are also shown. NA, not applicable.
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tion of colonic IL-12 in IL-102/2 mice. The results in Fig. 4A
demonstrate detection of significantly higher levels of colonic
IL-12 in SPF IL-102/2 mice than in SPF IL-101/1 mice, in both
the presence and absence of H. hepaticus colonization. H. he-
paticus colonization of SPF IL-102/2 mice did not increase
colonic IL-12 levels. Colonic IL-12 in SPF IL-102/2 mice did
not show significant differences at the various time points, and
at no time were differences seen in mice with or without H.
hepaticus (data not shown). Colonic fragment culture superna-
tants from IL-102/2 mice monoassociated with H. hepaticus in
both strains of IL-102/2 mice contained only low levels of
IL-12, which were not significantly different from the amounts
of IL-12 detected in colonic supernatants from germfree IL-
102/2 mice (Fig. 4B). IL-12 levels in colon culture superna-
tants from IL-102/2 mice monoassociated with H. hepaticus for
16 weeks since birth also did not significantly differ from those
of germfree littermates (data not shown).
T-cell activation of CD41 MLN cells. As shown in Table 2,
we detected statistically significant albeit limited differences in
the expression of some but not all T-cell activation markers
among gnotobiotic IL-102/2 mice on the 129/SvEv back-
ground. We observed higher proportions of CD691 CD41 T
cells and of CD41 T cells that express high levels of CD44 and
low levels of CD45RB in MLN of some H. hepaticus-monoas-
sociated IL-102/2 mice than in IL-102/2 germfree mice. We
did not observe significant differences when we compared the
expression of these cell surface molecules on CD41 MLN T
cells from H. hepaticus-monoassociated IL-102/2 mice on a
C57BL/6 3 129/Ola background with those in germfree IL-
102/2 on the same background (data not shown). It is inter-
esting, however, that MLN from germfree 129/SvEv IL-102/2
mice contain a significantly higher proportion of CD41 T cells
(42.7% 6 1.2%) than do germfree IL-102/2 mice on a C57BL/
6 3 129/Ola background (30.9% 6 4.9%) (P , 0.005). In SPF
IL-102/2 mice there was not a significant increase in T-cell
activation with H. hepaticus colonization. However, there were
fewer CD44hi T cells in SPF IL-102/2 mice colonized with
H. hepaticus.
DISCUSSION
Spontaneous H. hepaticus infection has been detected in
IL-102/2 mice with colitis, including our conventional colony
of C57BL/6 3 129/Ola IL-102/2 mice (30). To establish if H.
hepaticus that is endogenous to our colony could induce and/or
potentiate colitis in IL-102/2 mice, we compared the time
FIG. 3. Representative photomicrographs of tissue sections from the cecum of an IL-102/2 mouse colonized for 8 weeks with H. hepaticus-negative SPF flora (A),
an IL-102/2 mouse colonized for 8 weeks with H. hepaticus-positive SPF flora (B), a gnotobiotic IL-102/2 mouse monoassociated with H. hepaticus for 16 weeks since
birth (C), and an IL-101/1 SPF mouse (D). Note the extensive transmural inflammation in sections of the cecum of SPF IL-102/2 mice with or without H. hepaticus.
Only very mild cecal inflammation with a few submucosal lymphocytes was observed in some IL-102/2 mice monoassociated with H. hepaticus.
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course of development of colitis in germfree IL-102/2 mice
colonized with the endogenous H. hepaticus 2 days after trans-
fer to an SPF environment with that in littermates similarly
conventionalized but remaining free of H. hepaticus. Our re-
sults show that adolescent and young adult IL-102/2 mice
develop a rapid onset of colitis within 1 week after colonization
with SPF flora, with no influence on either the aggressiveness
of inflammation or the rate of progression when endogenous
H. hepaticus was persistently present. The lack of a potentiat-
ing or accelerating effect of native H. hepaticus on colonic
inflammation is most definitely evident at 1 week, when cecal
inflammation is relatively mild, so that a potentiating effect
could be more easily recognized. Since progressive, severe
typhlitis and colitis developed in the absence of H. hepaticus, as
determined by PCR, we conclude that the endogenous H. he-
paticus in our IL-102/2 mice is not required to induce colitis,
confirming earlier observations (30). Novel features of the pres-
ent study which advance our previous observations that SPF
bacteria devoid of H. hepaticus can induce aggressive colitis in
C57BL/6 3 129 Ola IL-102/2 mice (30) are a direct compar-
ison of IL-102/2 mice colonized with SPF bacteria with and
without H. hepaticus, monoassociation with a defined H. he-
paticus strain, and the failure to detect other Helicobacter spe-
cies in the SPF flora by PCR using Helicobacter consensus
primers (12). We can therefore also conclude that colitis in our
colony of an SPF IL-102/2 mouse strain is not caused by
(known) Helicobacter species but is more likely the result of an
interplay between commensal, nonpathogenic intestinal bacte-
ria in a susceptible host which has a defect in immune ho-
meostasis. This hypothesis is consistent with observations in a
number of models, including HLA-B27 transgenic rats (22),
IL-22/2 mice (5, 29), and mice lacking the T-cell receptor a
gene (8). We have documented by PCR the absence of Heli-
cobacter species in our SPF HLA-B27 transgenic rats (R. K.
Sellon, unpublished data) and in SPF IL-22/2 and Tgε26 trans-
genic mice, all of which develop active Th1-mediated colitis
(22, 29, 34).
Our monoassociation results indicate that at least the strain
of H. hepaticus that we investigated is not able to induce colitis
in our IL-102/2 mice in the absence of other bacteria, since
selective colonization with H. hepaticus for at least 9 to 16
weeks did not induce aggressive experimental colitis in gnoto-
biotic IL-102/2 mice either on a mixed C57BL/6 3 129/Ola
background or on an inbred 129/SvEv background. Monoas-
sociated IL-102/2 mice had no increased colonic histologic
scores or IL-12 production relative to SPF IL-101/1 or germ-
free IL-102/2 controls. Persistent H. hepaticus colonization
was documented by PCR and culture. It should be noted that
in IL-102/2 mice, no single bacterial species has been shown to
induce colitis, although HLA-B27 transgenic rats monoassoci-
ated with Bacteroides vulgatus develop colonic inflammation,
FIG. 4. IL-12 concentrations measured in supernatants of colon fragment cultures of IL-102/2 mice 8 weeks after SPF colonization with or without H. hepaticus
(A) and in IL-102/2 mice 9 and 16 weeks after monoassociation with H. hepaticus or in germfree mice (B). Values for SPF IL-101/1 mice are also shown (A). Values
(means 6 standard deviations) represent picograms of p40 IL-12 per 50 mg of tissue as detected by enzyme-linked immunosorbent assay. p, P , 0.05 compared to
colonic IL-12 levels from SPF IL-101/1 mice.
TABLE 2. Expression of cell surface activation markers on CD41 MLN T cells from IL-102/2 mice
in the absence or presence of H. hepaticus
Mice Status and time of sacrifice
% (mean 6 SD)a of CD41 T cells expressing the following phenotype:
CD69pos CD44hi CD45RBlo CD62Lneg
129/SvEv IL-102/2 Germfree 7.7 6 1.5 1.6 6 0.5 27.7 6 13.6 29.6 6 3.8
H. hepaticus monoassociated, 9 wk 8.1 6 1.4 3.5** 6 2.1 42.7** 6 7.2 29.3 6 5.2
H. hepaticus monoassociated, 16 wk 9.7** 6 1.0 2.3** 6 0.5 31.9 6 5.5 27.6 6 2.8
C57BL/6 3 129/Ola IL-102/2 SPFb, H. hepaticus negative, 8 wk 11.1 6 1.1 12.8 6 2.0 44.1 6 4.2 46.8 6 4.6
SPF, H. hepaticus positive, 8 wk 11.4 6 3.5 7.8* 6 3.9 50.9 6 8.3 50.0 6 6.1
a **, P , 0.01 versus germfree; *, P , 0.05 versus SPF, H. hepaticus negative.
b Mice were colonized with SPF flora.
VOL. 68, 2000 HELICOBACTER HEPATICUS IN IL-10-KNOCKOUT MICE 5111
establishing a precedent for a single organism to induce im-
mune-mediated colitis in genetically engineered rodents (23).
Our results concerning the role of H. hepaticus in IL-102/2
mice are different from previous reports. Fox et al. (16) colo-
nized germfree Swiss Webster mice with the same strain of
H. hepaticus used in this study and reported persistent hepatitis
and enterocolitis. These differences could be explained by ge-
netic host factors. Another reason for the divergent results is
the longer duration of H. hepaticus colonization in Swiss Web-
ster mice, in which minimal to mild colitis developed only after
28 to 33 weeks of colonization. In the present study, monoas-
sociated IL-102/2 mice were examined after 9 weeks of colo-
nization with H. hepaticus. Although the kinetics of colitis
development can be different in monoassociated mice, we
wanted to explore the effect of H. hepaticus within the time
frame that colitis develops in IL-102/2 mice moved from germ-
free to SPF conditions. However, only minimal inflammation
of the cecum was observed in 16-week-old IL-102/2 mice that
were monoassociated with H. hepaticus at birth.
Even if H. hepaticus is not required to induce colitis in
IL-102/2 mice, this organism could potentiate inflammation
induced by nonpathogenic commensal bacteria. We therefore
compared histologic and immunologic parameters between IL-
102/2 mice at several times after transfer to a SPF environ-
ment in the presence or absence of endogenous H. hepaticus.
Longer exposure of IL-102/2 mice to SPF flora worsened the
severity of colitis, especially in the cecum. However, our results
consistently reveal that the persistent presence of H. hepaticus
did not potentiate typhlitis and colitis at the onset or advanced
stage of disease in these mice as determined by blinded histo-
logic scores for different regions of the cecum and colon and
levels of colonic IL-12.
Our results are in contrast to a recent study by Kullberg et al.
(19), who reported that H. hepaticus triggered colitis in SPF
IL-102/2 mice through IL-12- and gamma interferon-depen-
dent mechanisms. Several differences in the experimental de-
signs of the two studies could explain these discrepant results.
One potential explanation for the different outcomes is that we
colonized our IL-102/2 mice with an endogenous H. hepaticus
strain, whereas Kullberg et al. (19) used the original Frederick
isolate (ATCC 51488) derived from A/JCr mice (13, 37). How-
ever, we clearly demonstrated that monoassociation of our
IL-102/2 mice with the same H. hepaticus strain (ATCC 51488)
used by Fox et al. (16) and Kullberg et al. (19) did not result in
significant colitis. An additional difference in the two studies is
the method of H. hepaticus colonization. In the study of Kull-
berg et al., IL-102/2 mice were inoculated with H. hepaticus
intraperitoneally and intragastrically (19), whereas in our
study, oral feeding and enemas containing SPF enteric flora
with H. hepaticus were used. We chose the oral-fecal coloni-
zation method because this mode of transmission more accu-
rately reflects physiologic transfer of this organism than does a
parenteral route (16, 19). An important methodologic differ-
ence which could explain the discrepancy between our results
and those of Kullberg et al. (19) is that we colonized germfree
IL-102/2 mice with SPF bacteria with or without H. hepaticus
at 2 months of age, whereas the IL-102/2 mice in the previous
study were born in an SPF environment and colonized with
H. hepaticus at 6 to 9 weeks of age. We have demonstrated that
older germfree mice colonized with SPF bacteria develop more
aggressive cecal inflammation and colitis than mice born into
an SPF environment (30). Another reason for the divergent
results with the study of Kullberg et al. could be differences in
the composition of the intestinal flora, other than H. hepaticus,
in the animal facilities of the two institutions. However, to date
specific inducing organisms in IL-102/2 mice still need to be
clarified.
It is also possible that failure to induce and potentiate colitis
in our IL-102/2 mice, in contrast to the results of Kullberg et
al. (19), is due to genetic differences between the strains of
IL-102/2 mice used in the two studies. We investigated IL-
102/2 mice on a mixed C57BL/6 3 129 Ola background as well
as inbred 129/SvEv IL-102/2 mice, whereas Kullberg et al.
used inbred C57BL/10SgSnAi IL-102/2 mice (19). Berg et al.
(1) have demonstrated important differences in the suscepti-
bilities of inbred IL-102/2 mice on different genetic back-
grounds to colitis and colon cancer. In the studies 129/SvEv
IL-102/2 mice developed aggressive inflammation, whereas
C57/BL6 IL-102/2 mice had mild, delayed-onset disease. IL-
102/2 mice on a mixed background developed intermediate
disease (1). Differences in genetic background as well as other
host factors mentioned above could explain why the SPF
C57BL/10 IL-102/2 mice without H. hepaticus used by Kull-
berg et al. had very little colitis. In support of our observations,
a preliminary report by Czinn et al. showed no potentiation of
colitis in SPF IL-102/2 mice on a C57BL/10 background by
colonization with H. hepaticus strain ATCC 51488 (6).
Except for the development of colitis in older Swiss Webster
(16) and A/JCr mice (15, 37), most of the initial studies re-
porting H. hepaticus-induced colitis and hepatitis focused on
immunodeficient mice, such as nude (11, 36) and SCID (20)
mice, which lack functional T cells, demonstrating that H. he-
paticus can induce disease in the absence of T cells. However,
the worsening of colitis in SCID mice reconstituted with CD45
RBhi CD41 T cells (3) and the findings of Kullberg et al. in
C57BL/10 IL-102/2 mice (19) indicate not only that immuno-
competent mice can develop colitis in the presence of this
organism but also that disease can occur in animals that have
functional T lymphocytes. In immunocompetent mice, H. hepati-
cus-induced colitis or chronic active hepatitis is accompanied
by a Th1 cytokine response (19, 38). Not only did H. hepaticus
infection not induce or potentiate colitis in our IL-102/2 mice,
but it also did not significantly affect the levels of mucosal
Th1-associated cytokines. Colonic culture IL-12 concentra-
tions were no different in SPF mice with or without H. hepati-
cus infection and were not increased by monoassociation of
germfree IL-102/2 mice with H. hepaticus. Increased colonic
culture IL-12 concentrations in SPF IL-102/2 mice indicate a
vigorous Th1 cytokine response following SPF colonization
with normal resident bacteria in the absence of H. hepaticus.
However, this Th1 response in SPF IL-102/2 mice was not
influenced by the presence of H. hepaticus at any time during
the development of colitis.
In conclusion, oral-fecal colonization with H. hepaticus
(ATCC 51448) did not induce significant colitis in monoasso-
ciated IL-102/2 mice, nor was colitis potentiated in SPF IL-
102/2 mice cocolonized with endogenous H. hepaticus, when
mice were monitored to the aggressive stage of disease. This
study indicates that H. hepaticus is not required for induction
of colitis in IL-102/2 mice and suggests that the ability of
H. hepaticus to induce colitis depends on the interaction be-
tween this organism and genetic or immunologic host factors.
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